 Pyrrolidines
"Pyrrolidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH.
| Descriptor ID |
D011759
|
| MeSH Number(s) |
D03.383.773
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrrolidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrrolidines".
This graph shows the total number of publications written about "Pyrrolidines" by people in this website by year, and whether "Pyrrolidines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 2004 | 1 | 2 | 3 | | 2007 | 1 | 1 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 1 | 0 | 1 | | 2013 | 1 | 2 | 3 | | 2014 | 0 | 2 | 2 | | 2015 | 0 | 5 | 5 | | 2016 | 1 | 0 | 1 | | 2017 | 1 | 2 | 3 | | 2018 | 3 | 3 | 6 | | 2019 | 4 | 2 | 6 | | 2020 | 1 | 0 | 1 | | 2021 | 2 | 4 | 6 | | 2022 | 0 | 4 | 4 | | 2023 | 0 | 1 | 1 | | 2024 | 1 | 3 | 4 | | 2025 | 5 | 1 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrrolidines" by people in Profiles.
-
Durieu I, Clements B, Fabrizzi B, Mall MA, McKone E, Ramsey B, Tullis E, Taylor-Cousar JL, van der Meer R, Bachman E, Chin A, Conner S, Jennings M, Weinstock T, Colombo C, Robinson P. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial. Am J Respir Crit Care Med. 2025 Oct; 211(10):1926-1934.
-
Daines CL, Polineni D, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Quon BS, Ringshausen FC, Selvadurai H, Taylor-Cousar JL, Withers NJ, Sawicki GS, Lee T, Ahluwalia N, Morlando Geiger J, Jennings M, Tan YV, Waltz D, Ramsey B, Griese M. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study. Am J Respir Crit Care Med. 2025 10; 211(10):1901-1914.
-
Abi-Aad SJ, Trocchia C, Mosha M, Mark JA, Leung DH, Khalaf R. Gastrointestinal Burden in Patients With Pancreatic Insufficient Cystic Fibrosis Before and After Elexacaftor/Tezacaftor/Ivacaftor Use. Pancreas. 2025 Nov-Dec 01; 54(10):e858-e862.
-
Wood C, Moheet A, Vigers T, Granados A, Lorenz A, Hanley E, Zemanick E, Chan CL. Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor-tezacaftor-ivacaftor. J Cyst Fibros. 2025 Jul; 24(4):755-758.
-
Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025 Mar; 13(3):256-271.
-
Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G. Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. Lancet Respir Med. 2025 Mar; 13(3):244-255.
-
Metcalf A, Martiniano SL, Sagel SD, Zaretsky MV, Zemanick ET, Hoppe JE. Outcomes of prenatal use of elexacaftor/tezacaftor/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis. J Cyst Fibros. 2025 May; 24(3):466-468.
-
Mayer-Hamblett N, Gifford AH, Kloster M, Russell R, Braun AT, Gibson RL, Hoppe JE, Jain R, Linnemann RW, Liou TG, Lysinger J, Milla C, Riekert KA, Sawicki GS, Young J, Nichols D. Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis. Ann Am Thorac Soc. 2024 Nov; 21(11):1507-1515.
-
Duong JT, Pope CE, Hayden HS, Miller C, Salipante SJ, Rowe SM, Solomon GM, Nichols D, Hoffman LR, Narkewicz MR, Green N. Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros. 2024 May; 23(3):490-498.
-
Ramsey B, Correll CU, DeMaso DR, McKone E, Tullis E, Taylor-Cousar JL, Chu C, Volkova N, Ahluwalia N, Waltz D, Tian S, Mall MA. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events. Am J Respir Crit Care Med. 2024 02 01; 209(3):299-306.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|